Predicted to enable Wnt receptor activity and Wnt-protein binding activity. Predicted to be involved in canonical Wnt signaling pathway; non-canonical Wnt signaling pathway; and positive regulation of JNK cascade. Predicted to act upstream of or within Wnt signaling pathway. Predicted to be located in cell surface; cytoplasm; and nucleoplasm. Orthologous to human FZD10 (frizzled class receptor 10); PARTICIPATES IN Wnt signaling pathway; Wnt signaling, canonical pathway; INTERACTS WITH bisphenol A; copper atom; copper(0).
[bisphenol A results in increased susceptibility to Estradiol] which results in increased expression of FZD10 mRNA and ESR1 protein promotes the reaction [Estradiol results in decreased expression of FZD10 mRNA]
[Estradiol co-treated with Progesterone] results in decreased expression of FZD10 mRNA and [Estradiol co-treated with TGFB1 protein] results in increased expression of FZD10 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA